UroGen Pharma (URGN) Financials

$4.19 +0.11 (+2.70%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$4.16 -0.04 (-0.84%)

As of 05/23/2025 07:59 PM Eastern

Annual Income Statements for UroGen Pharma

This table shows UroGen Pharma's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Income / (Loss) Attributable to Common Shareholders	-127	-102	-110
Consolidated Net Income / (Loss)	-127	-102	-110
Net Income / (Loss) Continuing Operations	-127	-102	-110
Total Pre-Tax Income	-124	-98	-108
Total Operating Income	-97	-66	-79
Total Gross Profit	82	73	57
Total Revenue	90	83	64
Operating Revenue	90	83	64
Total Cost of Revenue	8.88	9.36	7.65
Operating Cost of Revenue	8.88	9.36	7.65
Total Operating Expenses	178	139	136
Selling, General & Admin Expense	121	93	83
Research & Development Expense	57	46	53
Total Other Income / (Expense), net	-27	-33	-29
Interest Expense	13	15	8.44
Interest & Investment Income	8.67	3.48	1.01
Other Income / (Expense), net	-23	-22	-22
Income Tax Expense	2.83	3.92	1.76
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)	-0.04	-0.12	0.08
Basic Earnings per Share	($2.96)	($3.55)	($4.81)
Weighted Average Basic Shares Outstanding	42.88M	28.83M	22.81M
Weighted Average Diluted Shares Outstanding	46.09M	34.12M	23.44M
Weighted Average Basic & Diluted Shares Outstanding	46.09M	34.12M	23.44M

This table shows UroGen Pharma's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-38	-23	-33	-32	-26	-22	-24	-30	-29	-26
Consolidated Net Income / (Loss)	-38	-24	-33	-32	-26	-22	-24	-30	-29	-26
Net Income / (Loss) Continuing Operations	-38	-24	-33	-32	-26	-22	-24	-30	-29	-26
Total Pre-Tax Income	-35	-24	-33	-32	-22	-22	-24	-30	-28	-25
Total Operating Income	-28	-18	-26	-26	-15	-14	-15	-22	-20	-18
Total Gross Profit	22	23	20	17	21	18	19	15	16	14
Total Revenue	25	25	22	19	24	21	21	17	18	16
Operating Revenue	25	25	22	19	24	21	21	17	18	16
Total Cost of Revenue	2.47	2.45	2.23	1.73	2.29	2.37	2.44	2.27	2.26	2.02
Operating Cost of Revenue	2.47	2.45	2.23	1.73	2.29	2.37	2.44	2.27	2.26	2.02
Total Operating Expenses	50	40	45	43	36	32	34	37	36	32
Selling, General & Admin Expense	35	29	30	27	25	22	22	24	22	19
Research & Development Expense	15	11	15	15	11	10	12	12	14	13
Total Other Income / (Expense), net	-7.21	-6.04	-7.53	-6.49	-7.55	-8.39	-8.70	-8.15	-7.90	-7.04
Interest Expense	3.89	2.72	3.46	2.45	3.59	3.82	3.76	3.55	3.22	2.69
Interest & Investment Income	2.75	2.60	1.71	1.62	1.54	0.91	0.41	0.63	0.41	0.48
Other Income / (Expense), net	-6.06	-5.92	-5.77	-5.66	-5.51	-5.48	-5.34	-5.22	-5.08	-4.82
Income Tax Expense	2.65	0.09	0.04	0.05	3.85	-0.01	0.05	0.02	0.69	0.71
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)	0.18	-0.27	-0.01	0.05	-0.15	-0.02	0.11	-0.06	-	0.10
Basic Earnings per Share	($0.53)	($0.55)	($0.91)	($0.97)	($0.54)	($0.68)	($1.03)	($1.30)	($1.25)	($1.13)
Weighted Average Basic Shares Outstanding	42.88M	43.10M	36.82M	33.38M	28.83M	32.30M	23.46M	23.28M	22.81M	22.80M
Weighted Average Diluted Shares Outstanding	46.09M	42.20M	42.11M	36.13M	34.12M	30.87M	30.28M	23.45M	23.44M	23.09M
Weighted Average Basic & Diluted Shares Outstanding	46.09M	42.20M	42.11M	36.13M	34.12M	30.87M	30.28M	23.45M	23.44M	23.09M

This table details how cash moves in and out of UroGen Pharma's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Change in Cash & Equivalents	77	40	11
Net Cash From Operating Activities	-97	-76	-88
Net Cash From Continuing Operating Activities	-97	-76	-88
Net Income / (Loss) Continuing Operations	-127	-102	-110
Consolidated Net Income / (Loss)	-127	-102	-110
Depreciation Expense	0.33	0.80	0.92
Amortization Expense	-3.34	-0.02	2.15
Non-Cash Adjustments To Reconcile Net Income	28	21	24
Changes in Operating Assets and Liabilities, net	4.88	4.32	-5.18
Net Cash From Investing Activities	-21	-0.95	1.06
Net Cash From Continuing Investing Activities	-21	-0.95	1.06
Purchase of Property, Plant & Equipment	-0.30	-0.19	-0.25
Purchase of Investments	-128	-50	-63
Sale and/or Maturity of Investments	108	49	64
Net Cash From Financing Activities	195	117	97
Net Cash From Continuing Financing Activities	195	117	97
Issuance of Debt	24	0.00	96
Issuance of Common Equity	170	116	0.00
Other Financing Activities, net	0.32	0.87	1.51

This table details how cash moves in and out of UroGen Pharma's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	47	-95	89	36	-24	99	-16	-19	27	-52
Net Cash From Operating Activities	-14	-28	-24	-32	-13	-17	-20	-26	-22	-18
Net Cash From Continuing Operating Activities	-14	-28	-24	-32	-13	-17	-20	-26	-22	-18
Net Income / (Loss) Continuing Operations	-38	-24	-33	-32	-26	-22	-24	-30	-29	-26
Consolidated Net Income / (Loss)	-38	-24	-33	-32	-26	-22	-24	-30	-29	-26
Depreciation Expense	0.07	0.07	0.07	0.12	0.19	0.19	0.21	0.22	0.24	0.24
Amortization Expense	-1.07	-1.47	0.12	-0.92	-1.05	0.49	0.27	0.27	0.49	0.61
Non-Cash Adjustments To Reconcile Net Income	9.37	6.56	7.20	5.11	6.17	4.69	4.83	5.16	5.34	5.17
Changes in Operating Assets and Liabilities, net	16	-9.15	2.27	-3.76	7.80	-0.79	-1.44	-1.24	1.05	2.20
Net Cash From Investing Activities	61	-107	12	14	-11	0.40	3.72	6.27	23	-35
Net Cash From Continuing Investing Activities	61	-107	12	14	-11	0.40	3.72	6.27	23	-35
Purchase of Property, Plant & Equipment	-0.12	-0.10	-0.08	0.00	-0.06	-0.10	-0.02	-0.02	-0.01	-0.15
Purchase of Investments	-9.23	-119	-	0.00	-15	-11	-	-24	-	-63
Sale and/or Maturity of Investments	70	12	12	14	3.54	11	3.74	30	23	28
Net Cash From Financing Activities	0.07	40	100	55	0.04	116	0.14	0.67	25	1.10
Net Cash From Continuing Financing Activities	0.07	40	100	55	0.04	116	0.14	0.67	25	1.10
Other Financing Activities, net	0.07	0.12	0.14	0.00	0.04	0.02	0.14	0.67	0.38	1.12

This table presents UroGen Pharma's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Total Assets	286	178	136
Total Current Assets	276	169	129
Cash & Equivalents	172	95	55
Restricted Cash	1.08	0.82	0.81
Short-Term Investments	65	42	45
Accounts Receivable	20	15	13
Inventories, net	9.23	5.67	4.33
Prepaid Expenses	8.85	10	11
Plant, Property, & Equipment, net	0.66	0.69	1.30
Total Noncurrent Assets	8.92	8.44	5.42
Long-Term Investments	5.20	4.73	0.22
Other Noncurrent Operating Assets	3.72	3.71	5.19
Total Liabilities & Shareholders' Equity	286	178	136
Total Liabilities	295	244	225
Total Current Liabilities	46	31	24
Accounts Payable	27	17	12
Current Employee Benefit Liabilities	11	11	8.26
Other Current Liabilities	7.95	3.86	3.28
Total Noncurrent Liabilities	249	212	201
Long-Term Debt	122	99	98
Capital Lease Obligations	1.65	0.84	-
Noncurrent Deferred & Payable Income Tax Liabilities	3.79	3.19	3.02
Other Noncurrent Operating Liabilities	121	110	101
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-8.80	-65	-89
Total Preferred & Common Equity	-8.80	-65	-89
Total Common Equity	-8.80	-65	-89
Common Stock	797	614	488
Retained Earnings	-806	-679	-577
Accumulated Other Comprehensive Income / (Loss)	0.06	0.01	-0.11

This table presents UroGen Pharma's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	302	282	201	194	95	113	128
Total Current Assets	295	279	197	182	81	96	122
Cash & Equivalents	125	220	131	119	20	37	29
Restricted Cash	1.07	0.83	0.82	0.82	0.82	0.81	0.81
Short-Term Investments	125	21	33	28	27	29	67
Accounts Receivable	23	17	14	13	16	12	9.43
Inventories, net	7.59	7.44	7.24	5.00	4.99	5.47	4.86
Prepaid Expenses	14	12	10	16	13	12	11
Plant, Property, & Equipment, net	0.61	0.58	0.57	0.82	0.91	1.10	1.52
Total Noncurrent Assets	6.24	2.30	3.25	11	13	16	5.36
Long-Term Investments	4.82	0.38	0.71	6.73	8.19	10	0.22
Other Noncurrent Operating Assets	1.42	1.92	2.54	3.96	4.92	5.49	5.14
Total Liabilities & Shareholders' Equity	302	282	201	194	95	113	128
Total Liabilities	276	252	241	236	234	230	192
Total Current Liabilities	33	34	26	26	27	25	19
Accounts Payable	20	24	18	14	16	17	9.36
Current Employee Benefit Liabilities	9.03	6.85	4.99	8.15	6.72	4.92	6.63
Other Current Liabilities	4.07	3.62	3.20	3.55	3.64	3.19	3.02
Total Noncurrent Liabilities	244	217	214	210	207	204	173
Long-Term Debt	122	98	98	99	98	98	72
Noncurrent Deferred & Payable Income Tax Liabilities	3.19	3.19	3.19	3.02	3.02	3.02	2.84
Other Noncurrent Operating Liabilities	119	116	114	108	106	103	98
Commitments & Contingencies	0.00	-	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	26	30	-40	-42	-138	-117	-63
Total Preferred & Common Equity	26	30	-40	-42	-138	-117	-63
Total Common Equity	26	30	-40	-42	-138	-117	-63
Common Stock	794	775	672	611	493	491	485
Retained Earnings	-769	-745	-712	-653	-631	-607	-548
Accumulated Other Comprehensive Income / (Loss)	0.24	-0.03	-0.04	-0.13	-0.15	-0.05	-0.16

This table displays calculated financial ratios and metrics derived from UroGen Pharma's official financial filings.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Growth Metrics	-	-	-
Revenue Growth	9.29%	28.52%	33.96%
EBITDA Growth	-42.75%	11.51%	9.14%
EBIT Growth	-38.01%	13.43%	8.20%
NOPAT Growth	-47.68%	17.09%	14.36%
Net Income Growth	-24.09%	6.87%	0.94%
EPS Growth	0.00%	0.00%	0.00%
Operating Cash Flow Growth	-26.70%	12.77%	-3.14%
Free Cash Flow Firm Growth	-57.10%	33.05%	-590.82%
Invested Capital Growth	-18.50%	-16.71%	-12.04%
Revenue Q/Q Growth	1.16%	7.04%	3.07%
EBITDA Q/Q Growth	-13.50%	4.08%	2.04%
EBIT Q/Q Growth	-12.77%	5.68%	1.85%
NOPAT Q/Q Growth	-15.58%	7.97%	-0.47%
Net Income Q/Q Growth	-9.96%	2.71%	-0.38%
EPS Q/Q Growth	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	-0.65%	10.29%	-1.96%
Free Cash Flow Firm Q/Q Growth	2.28%	23.64%	3.30%
Invested Capital Q/Q Growth	-18.60%	-10.05%	-5.05%
Profitability Metrics	-	-	-
Gross Margin	90.18%	88.68%	88.11%
EBITDA Margin	-136.29%	-104.34%	-151.54%
Operating Margin	-107.06%	-79.23%	-122.82%
EBIT Margin	-132.96%	-105.29%	-156.32%
Profit (Net Income) Margin	-140.35%	-123.61%	-170.58%
Tax Burden Percent	102.28%	103.99%	101.62%
Interest Burden Percent	103.20%	112.90%	107.38%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%
Return on Equity (ROE)	342.83%	132.29%	271.24%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-51.80%	-55.48%	-78.79%
Return on Assets (ROA)	-54.68%	-65.14%	-85.98%
Return on Common Equity (ROCE)	342.83%	132.29%	271.24%
Return on Equity Simple (ROE_SIMPLE)	1,441.26%	156.79%	122.85%
Net Operating Profit after Tax (NOPAT)	-68	-46	-55
NOPAT Margin	-74.94%	-55.46%	-85.97%
Net Nonoperating Expense Percent (NNEP)	-72.68%	-242.01%	-114.97%
Return On Investment Capital (ROIC_SIMPLE)	-59.12%	-134.20%	-
Cost of Revenue to Revenue	9.82%	11.32%	11.89%
SG&A Expenses to Revenue	134.02%	112.77%	128.72%
R&D to Revenue	63.21%	55.15%	82.21%
Operating Expenses to Revenue	197.24%	167.92%	210.92%
Earnings before Interest and Taxes (EBIT)	-120	-87	-101
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-123	-86	-98
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00
Price to Revenue (P/Rev)	4.97	5.60	3.18
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	3.65	5.08	3.13
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	-14.02	-1.52	-1.09
Long-Term Debt to Equity	-14.02	-1.52	-1.09
Financial Leverage	2.20	0.30	1.17
Leverage Ratio	-6.27	-2.03	-3.15
Compound Leverage Factor	-6.47	-2.29	-3.39
Debt to Total Capital	107.68%	290.77%	1,192.97%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	107.68%	290.77%	1,192.97%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	-7.68%	-190.77%	-1,092.97%
Debt to EBITDA	-1.00	-1.15	-1.00
Net Debt to EBITDA	0.97	0.50	0.04
Long-Term Debt to EBITDA	-1.00	-1.15	-1.00
Debt to NOPAT	-1.82	-2.17	-1.76
Net Debt to NOPAT	1.77	0.94	0.06
Long-Term Debt to NOPAT	-1.82	-2.17	-1.76
Altman Z-Score	-3.14	-4.41	-6.46
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	6.01	5.42	5.39
Quick Ratio	5.59	4.88	4.71
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-48	-30	-45
Operating Cash Flow to CapEx	-32,802.03%	-39,369.07%	-34,472.05%
Free Cash Flow to Firm to Interest Expense	-3.81	-2.06	-5.38
Operating Cash Flow to Interest Expense	-7.73	-5.19	-10.38
Operating Cash Flow Less CapEx to Interest Expense	-7.75	-5.20	-10.41
Efficiency Ratios	-	-	-
Asset Turnover	0.39	0.53	0.50
Accounts Receivable Turnover	5.06	5.88	5.27
Inventory Turnover	1.19	1.87	1.67
Fixed Asset Turnover	134.52	83.30	39.43
Accounts Payable Turnover	0.40	0.65	0.63
Days Sales Outstanding (DSO)	72.16	62.10	69.25
Days Inventory Outstanding (DIO)	306.19	194.92	218.34
Days Payable Outstanding (DPO)	903.54	563.84	583.81
Cash Conversion Cycle (CCC)	-525.19	-306.81	-296.23
Capital & Investment Metrics	-	-	-
Invested Capital	-128	-108	-93
Invested Capital Turnover	-0.76	-0.82	-0.73
Increase / (Decrease) in Invested Capital	-20	-16	-9.97
Enterprise Value (EV)	330	420	201
Market Capitalization	449	463	205
Book Value per Share	($0.21)	($2.11)	($3.87)
Tangible Book Value per Share	($0.21)	($2.11)	($3.87)
Total Capital	115	34	8.18
Total Debt	123	99	98
Total Long-Term Debt	123	99	98
Net Debt	-120	-43	-3.46
Capital Expenditures (CapEx)	0.30	0.19	0.25
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-7.58	0.19	4.21
Debt-free Net Working Capital (DFNWC)	230	138	105
Net Working Capital (NWC)	230	138	105
Net Nonoperating Expense (NNE)	59	56	54
Net Nonoperating Obligations (NNO)	-120	-43	-3.46
Total Depreciation and Amortization (D&A)	-3.01	0.78	3.07
Debt-free, Cash-free Net Working Capital to Revenue	-8.38%	0.22%	6.55%
Debt-free Net Working Capital to Revenue	254.64%	166.81%	163.14%
Net Working Capital to Revenue	254.64%	166.81%	163.14%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($2.96)	($3.55)	($4.81)
Adjusted Weighted Average Basic Shares Outstanding	42.88M	28.83M	22.81M
Adjusted Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	46.09M	34.12M	23.44M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	46.09M	34.12M	23.44M
Normalized Net Operating Profit after Tax (NOPAT)	-68	-46	-55
Normalized NOPAT Margin	-74.94%	-55.46%	-85.97%
Pre Tax Income Margin	-137.22%	-118.87%	-167.86%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	-9.60	-5.92	-11.92
NOPAT to Interest Expense	-5.41	-3.12	-6.56
EBIT Less CapEx to Interest Expense	-9.62	-5.93	-11.95
NOPAT Less CapEx to Interest Expense	-5.43	-3.13	-6.59
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	-0.15%

This table displays calculated financial ratios and metrics derived from UroGen Pharma's official financial filings.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	4.40%	20.87%	3.35%	9.24%	30.06%	29.54%	27.31%	26.75%	11.86%	41.81%
EBITDA Growth	-65.58%	-35.85%	-55.18%	-20.19%	14.89%	17.04%	15.03%	0.78%	7.62%	25.61%
EBIT Growth	-67.65%	-23.61%	-52.52%	-15.15%	20.70%	17.14%	15.57%	1.85%	6.95%	24.32%
NOPAT Growth	-89.32%	-29.96%	-67.98%	-16.76%	27.97%	25.36%	17.81%	-0.40%	-1.84%	22.84%
Net Income Growth	-44.19%	-8.20%	-38.39%	-6.86%	9.88%	15.30%	9.57%	-6.41%	-1.47%	14.50%
EPS Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Growth	-4.79%	-59.92%	-17.14%	-22.97%	40.25%	1.78%	16.22%	-7.55%	-8.38%	4.68%
Free Cash Flow Firm Growth	-87.10%	-493.74%	-115.17%	-0.84%	225.08%	114.05%	156.78%	-106.96%	-107.05%	-107.83%
Invested Capital Growth	-18.50%	-9.95%	-18.36%	-13.97%	-16.71%	-11.41%	-15.98%	-12.72%	-12.04%	-10.19%
Revenue Q/Q Growth	-2.54%	15.36%	16.33%	-20.18%	12.84%	-1.36%	22.96%	-4.97%	12.39%	-3.05%
EBITDA Q/Q Growth	-39.69%	20.89%	2.39%	-60.41%	-14.60%	9.63%	24.40%	-8.70%	-11.71%	7.44%
EBIT Q/Q Growth	-43.74%	25.79%	-0.68%	-56.11%	-5.98%	8.43%	23.99%	-7.51%	-10.73%	6.69%
NOPAT Q/Q Growth	-57.64%	32.10%	-0.38%	-76.19%	-8.21%	12.24%	30.22%	-8.69%	-12.14%	3.36%
Net Income Q/Q Growth	-58.46%	29.13%	-3.46%	-24.10%	-18.91%	9.35%	20.11%	-4.66%	-11.76%	3.22%
EPS Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	50.77%	-16.49%	25.17%	-144.19%	24.87%	14.67%	21.44%	-18.64%	-23.51%	27.22%
Free Cash Flow Firm Q/Q Growth	127.43%	-549.88%	91.98%	-177.84%	737.19%	-74.96%	153.27%	-11.98%	5.96%	-1.20%
Invested Capital Q/Q Growth	-18.60%	5.18%	-5.58%	0.97%	-10.05%	-2.07%	-1.66%	-2.20%	-5.05%	-6.25%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	89.94%	90.27%	89.80%	90.80%	90.28%	88.65%	88.44%	86.83%	87.49%	87.45%
EBITDA Margin	-141.36%	-98.64%	-143.83%	-171.41%	-89.13%	-87.76%	-95.79%	-155.79%	-136.20%	-137.04%
Operating Margin	-112.59%	-69.61%	-118.27%	-137.05%	-62.09%	-64.74%	-72.77%	-128.23%	-112.10%	-112.36%
EBIT Margin	-137.27%	-93.08%	-144.69%	-167.19%	-85.48%	-91.02%	-98.05%	-158.61%	-140.19%	-142.30%
Profit (Net Income) Margin	-152.71%	-93.93%	-152.89%	-171.91%	-110.57%	-104.93%	-114.18%	-175.74%	-159.57%	-160.47%
Tax Burden Percent	107.60%	100.39%	100.11%	100.17%	117.39%	99.96%	100.22%	100.07%	102.45%	102.82%
Interest Burden Percent	103.39%	100.52%	105.55%	102.65%	110.18%	115.33%	116.19%	110.72%	111.11%	109.67%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	342.83%	1,400.39%	210.11%	133.15%	132.29%	199.65%	121.61%	167.04%	271.24%	688.94%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-53.49%	-33.57%	-65.22%	-89.91%	-45.05%	-43.67%	-58.88%	-77.39%	-70.66%	-67.55%
Return on Assets (ROA)	-59.50%	-33.87%	-68.91%	-92.45%	-58.26%	-50.34%	-68.57%	-85.75%	-80.43%	-76.17%
Return on Common Equity (ROCE)	342.83%	1,400.39%	210.11%	133.15%	132.29%	199.65%	121.61%	167.04%	271.24%	688.94%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-452.20%	-374.69%	259.92%	0.00%	250.27%	78.77%	95.75%	0.00%	172.81%
Net Operating Profit after Tax (NOPAT)	-19	-12	-18	-18	-10	-9.45	-11	-15	-14	-13
NOPAT Margin	-78.81%	-48.73%	-82.79%	-95.94%	-43.46%	-45.32%	-50.94%	-89.76%	-78.47%	-78.65%
Net Nonoperating Expense Percent (NNEP)	-22.31%	-11.98%	-29.89%	-61.63%	-67.79%	-30.49%	-10,127.73%	-65.10%	-30.98%	-19.25%
Return On Investment Capital (ROIC_SIMPLE)	-16.90%	-	-	-	-29.92%	-	-	-	-	-
Cost of Revenue to Revenue	10.06%	9.73%	10.20%	9.20%	9.72%	11.35%	11.56%	13.17%	12.51%	12.55%
SG&A Expenses to Revenue	141.90%	114.83%	137.57%	145.35%	104.34%	104.33%	106.41%	142.36%	119.58%	118.48%
R&D to Revenue	60.63%	45.05%	70.50%	82.50%	48.03%	49.06%	54.80%	72.70%	80.02%	81.34%
Operating Expenses to Revenue	202.53%	159.88%	208.06%	227.85%	152.37%	153.39%	161.21%	215.05%	199.60%	199.81%
Earnings before Interest and Taxes (EBIT)	-34	-23	-32	-31	-20	-19	-21	-27	-25	-23
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-35	-25	-31	-32	-21	-18	-20	-27	-25	-22
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	20.96	20.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	0.00	20.96	20.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	4.97	5.99	7.13	6.07	5.60	5.49	3.35	3.19	3.18	3.03
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	3.65	4.49	5.43	5.27	5.08	4.76	3.93	3.50	3.13	2.63
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	-14.02	4.77	3.23	-2.43	-1.52	-2.35	-0.71	-0.84	-1.09	-1.14
Long-Term Debt to Equity	-14.02	4.77	3.23	-2.43	-1.52	-2.35	-0.71	-0.84	-1.09	-1.14
Financial Leverage	2.20	11.54	0.95	0.30	0.30	0.77	0.00	0.34	1.17	4.31
Leverage Ratio	-6.27	-30.08	-3.49	-2.00	-2.03	-3.06	-1.35	-2.09	-3.15	-8.29
Compound Leverage Factor	-6.48	-30.23	-3.68	-2.05	-2.24	-3.53	-1.56	-2.31	-3.51	-9.09
Debt to Total Capital	107.68%	82.67%	76.34%	169.85%	290.77%	174.29%	-244.90%	-526.20%	1,192.97%	837.26%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	107.68%	82.67%	76.34%	169.85%	290.77%	174.29%	-244.90%	-526.20%	1,192.97%	837.26%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	-7.68%	17.33%	23.66%	-69.85%	-190.77%	-74.29%	344.90%	626.20%	-1,092.97%	-737.26%
Debt to EBITDA	-1.00	-1.12	-0.96	-1.07	-1.15	-1.09	-1.05	-1.01	-1.00	-0.72
Net Debt to EBITDA	0.97	1.23	1.42	0.75	0.50	0.63	-0.45	-0.22	0.04	0.25
Long-Term Debt to EBITDA	-1.00	-1.12	-0.96	-1.07	-1.15	-1.09	-1.05	-1.01	-1.00	-0.72
Debt to NOPAT	-1.82	-2.08	-1.75	-2.01	-2.17	-1.98	-1.85	-1.77	-1.76	-1.31
Net Debt to NOPAT	1.77	2.28	2.59	1.40	0.94	1.13	-0.79	-0.39	0.06	0.46
Long-Term Debt to NOPAT	-1.82	-2.08	-1.75	-2.01	-2.17	-1.98	-1.85	-1.77	-1.76	-1.31
Altman Z-Score	-2.14	-1.32	-1.28	-2.77	-3.17	-2.60	-7.92	-6.40	-4.62	-4.53
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	6.01	9.00	8.15	7.47	5.42	7.06	3.04	3.80	5.39	6.40
Quick Ratio	5.59	8.31	7.55	6.77	4.88	6.21	2.35	3.07	4.71	5.54
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.68	-2.48	-0.38	-4.77	5.28	0.63	2.52	-4.73	-4.22	-4.49
Operating Cash Flow to CapEx	-11,842.61%	-28,816.67%	-28,271.43%	0.00%	-23,207.14%	-17,299.00%	-135,160.00%	-112,204.35%	-167,323.08%	-11,511.11%
Free Cash Flow to Firm to Interest Expense	0.18	-0.91	-0.11	-1.95	1.47	0.17	0.67	-1.33	-1.31	-1.67
Operating Cash Flow to Interest Expense	-3.50	-10.17	-6.86	-12.97	-3.62	-4.53	-5.39	-7.26	-6.75	-6.54
Operating Cash Flow Less CapEx to Interest Expense	-3.53	-10.20	-6.89	-12.97	-3.64	-4.56	-5.39	-7.27	-6.75	-6.59
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.39	0.36	0.45	0.54	0.53	0.48	0.60	0.49	0.50	0.47
Accounts Receivable Turnover	5.06	5.01	5.16	6.33	5.88	6.94	5.35	6.18	5.27	7.25
Inventory Turnover	1.19	1.38	1.39	1.39	1.87	1.89	1.79	1.64	1.67	1.61
Fixed Asset Turnover	134.52	124.90	114.11	101.02	83.30	65.99	57.67	47.21	39.43	35.71
Accounts Payable Turnover	0.40	0.52	0.43	0.50	0.65	0.80	0.72	0.62	0.63	0.68
Days Sales Outstanding (DSO)	72.16	72.80	70.67	57.70	62.10	52.61	68.20	59.04	69.25	50.31
Days Inventory Outstanding (DIO)	306.19	264.35	263.47	262.85	194.92	192.78	203.69	222.24	218.34	226.69
Days Payable Outstanding (DPO)	903.54	708.68	851.18	729.83	563.84	458.09	508.47	588.46	583.81	533.85
Cash Conversion Cycle (CCC)	-525.19	-371.53	-517.04	-409.29	-306.81	-212.70	-236.58	-307.18	-296.23	-256.85
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-128	-108	-114	-108	-108	-98	-96	-95	-93	-88
Invested Capital Turnover	-0.76	-0.86	-0.81	-0.83	-0.82	-0.83	-0.81	-0.76	-0.73	-0.74
Increase / (Decrease) in Invested Capital	-20	-9.80	-18	-13	-16	-10	-13	-11	-9.97	-8.17
Enterprise Value (EV)	330	401	462	444	420	368	285	238	201	164
Market Capitalization	449	535	606	512	463	424	243	217	205	189
Book Value per Share	($0.21)	$0.61	$0.84	($1.18)	($2.11)	($1.39)	($5.90)	($4.97)	($3.87)	($2.78)
Tangible Book Value per Share	($0.21)	$0.61	$0.84	($1.18)	($2.11)	($1.39)	($5.90)	($4.97)	($3.87)	($2.78)
Total Capital	115	147	128	57	34	57	-40	-19	8.18	8.58
Total Debt	123	122	98	98	99	99	98	98	98	72
Total Long-Term Debt	123	122	98	98	99	99	98	98	98	72
Net Debt	-120	-134	-144	-68	-43	-56	42	22	-3.46	-25
Capital Expenditures (CapEx)	0.12	0.10	0.08	0.00	0.06	0.10	0.02	0.02	0.01	0.15
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-7.58	12	2.84	5.55	0.19	8.10	6.45	4.87	4.21	5.87
Debt-free Net Working Capital (DFNWC)	230	262	245	170	138	156	55	71	105	103
Net Working Capital (NWC)	230	262	245	170	138	156	55	71	105	103
Net Nonoperating Expense (NNE)	18	11	15	14	16	12	13	15	15	13
Net Nonoperating Obligations (NNO)	-120	-134	-144	-68	-43	-56	42	22	-3.46	-25
Total Depreciation and Amortization (D&A)	-1.01	-1.40	0.19	-0.79	-0.86	0.68	0.48	0.49	0.72	0.85
Debt-free, Cash-free Net Working Capital to Revenue	-8.38%	13.05%	3.34%	6.59%	0.22%	10.48%	8.90%	7.16%	6.55%	9.40%
Debt-free Net Working Capital to Revenue	254.64%	293.53%	287.90%	202.15%	166.81%	202.31%	75.25%	104.05%	163.14%	164.31%
Net Working Capital to Revenue	254.64%	293.53%	287.90%	202.15%	166.81%	202.31%	75.25%	104.05%	163.14%	164.31%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.53)	($0.55)	($0.91)	($0.97)	($0.54)	($0.68)	($1.03)	($1.30)	($1.25)	($1.13)
Adjusted Weighted Average Basic Shares Outstanding	42.88M	43.10M	36.82M	33.38M	28.83M	32.30M	23.46M	23.28M	22.81M	22.80M
Adjusted Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	46.09M	42.20M	42.11M	36.13M	34.12M	30.87M	30.28M	23.45M	23.44M	23.09M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	46.09M	42.20M	42.11M	36.13M	34.12M	30.87M	30.28M	23.45M	23.44M	23.09M
Normalized Net Operating Profit after Tax (NOPAT)	-19	-12	-18	-18	-10	-9.45	-11	-15	-14	-13
Normalized NOPAT Margin	-78.81%	-48.73%	-82.79%	-95.94%	-43.46%	-45.32%	-50.94%	-89.76%	-78.47%	-78.65%
Pre Tax Income Margin	-141.92%	-93.56%	-152.71%	-171.62%	-94.19%	-104.97%	-113.92%	-175.62%	-155.76%	-156.07%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-8.66	-8.62	-9.13	-12.83	-5.61	-4.97	-5.51	-7.67	-7.87	-8.50
NOPAT to Interest Expense	-4.97	-4.51	-5.23	-7.36	-2.85	-2.48	-2.86	-4.34	-4.41	-4.70
EBIT Less CapEx to Interest Expense	-8.69	-8.66	-9.16	-12.83	-5.62	-5.00	-5.51	-7.68	-7.87	-8.56
NOPAT Less CapEx to Interest Expense	-5.00	-4.55	-5.25	-7.36	-2.87	-2.50	-2.87	-4.35	-4.41	-4.76
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-0.15%	-0.16%

Frequently Asked Questions About UroGen Pharma's Financials

When does UroGen Pharma's fiscal year end?

According to the most recent income statement we have on file, UroGen Pharma's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has UroGen Pharma's net income changed over the last 2 years?

UroGen Pharma's net income appears to be on an upward trend, with a most recent value of -$126.87 million in 2024, rising from -$109.78 million in 2022. The previous period was -$102.24 million in 2023. Find out what analysts predict for UroGen Pharma in the coming months.

What is UroGen Pharma's operating income?

UroGen Pharma's total operating income in 2024 was -$96.78 million, based on the following breakdown:

Total Gross Profit: $81.52 million
Total Operating Expenses: $178.30 million

How has UroGen Pharma revenue changed over the last 2 years?

Over the last 2 years, UroGen Pharma's total revenue changed from $64.36 million in 2022 to $90.40 million in 2024, a change of 40.5%.

How much debt does UroGen Pharma have?

UroGen Pharma's total liabilities were at $294.51 million at the end of 2024, a 20.9% increase from 2023, and a 30.9% increase since 2022.

How much cash does UroGen Pharma have?

In the past 2 years, UroGen Pharma's cash and equivalents has ranged from $55.41 million in 2022 to $171.99 million in 2024, and is currently $171.99 million as of their latest financial filing in 2024.

How has UroGen Pharma's book value per share changed over the last 2 years?

Over the last 2 years, UroGen Pharma's book value per share changed from -3.87 in 2022 to -0.21 in 2024, a change of -94.6%.

Related Companies

This page (NASDAQ:URGN) was last updated on 5/24/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

UroGen Pharma (URGN) Financials

Frequently Asked Questions About UroGen Pharma's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

UroGen Pharma (URGN) Financials

Annual Income Statements for UroGen Pharma

Quarterly Income Statements for UroGen Pharma

Annual Cash Flow Statements for UroGen Pharma

Quarterly Cash Flow Statements for UroGen Pharma

Annual Balance Sheets for UroGen Pharma

Quarterly Balance Sheets for UroGen Pharma

Annual Metrics And Ratios for UroGen Pharma

Quarterly Metrics And Ratios for UroGen Pharma

Frequently Asked Questions About UroGen Pharma's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools